Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail)

v2.4.1.9
Description of Business and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended
Feb. 02, 2012
Dec. 31, 2005
Nov. 30, 2014
Agreement
Deliverables
Segment
CompensationPlan
Nov. 30, 2013
Oct. 10, 2001
Aug. 25, 2011
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Number of reportable segment     1us-gaap_NumberOfReportableSegments      
Concentration risk related to supplier     Company depends on one supplier for the source of its collection kits      
Number of deliverables for revenue recognized     2ccel_NumberOfDeliverablesForRevenueRecognized      
Deferred revenue recognition period     12 months      
Number of licensing agreement made by entity     12ccel_NumberOfLicensingAgreementMadeByEntity      
Number of license agreement     2ccel_NumberOfLicenseAgreement      
Cash required to be deposited in bank for issuance of letter of credit     $ 200,000us-gaap_CashCollateralForBorrowedSecurities      
Certificate of deposit with a principal balance     200,000us-gaap_CertificatesOfDepositAtCarryingValue      
Cash transferred to trust           2,500,000ccel_RestrictedCashTransferredToTrust
Period of doubtful for accounts receivable due from client     30 days      
Impairment on long lived assets     0us-gaap_ImpairmentOfLongLivedAssetsHeldForUse 0us-gaap_ImpairmentOfLongLivedAssetsHeldForUse    
Writing off abandoned patent and trademarks     25,649us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill 378,837us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill    
Amortization expense     28,000us-gaap_AmortizationOfIntangibleAssets 394,000us-gaap_AmortizationOfIntangibleAssets    
Accumulated amortization     6,212us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization 7,123us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization    
Amortization period     20 years      
Minimum percentage probability of realized tax benefit on settlement     50.00%ccel_MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement      
Provisions for interest or penalties related to uncertain tax positions     0us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions 0us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions    
Uncertain tax provisions     0us-gaap_LiabilityForUncertainTaxPositionsCurrent 0us-gaap_LiabilityForUncertainTaxPositionsCurrent    
Advertising cost included in selling, general and administrative expenses     621,000us-gaap_AdvertisingExpense 615,000us-gaap_AdvertisingExpense    
Unrealized holding gain and (loss)     (31,700)us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss 12,800us-gaap_TradingSecuritiesUnrealizedHoldingGainLoss    
Payment warranty   50,000ccel_PaymentWarranty        
Increased payment warranty 75,000ccel_IncreasedPaymentWarranty          
Additional payment warranty 10,000ccel_AdditionalPaymentWarranty          
Reserves recorded under programs     17,000ccel_ReservesRecordedUnderPrograms 16,000ccel_ReservesRecordedUnderPrograms    
Number of employee stock based compensation plan     3ccel_NumberOfEmployeeStockBasedCompensationPlan      
Stock option compensation expense     404,000us-gaap_AllocatedShareBasedCompensationExpense 272,000us-gaap_AllocatedShareBasedCompensationExpense    
Saneron [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Ownership interest     33.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= ccel_SaneronMember 		34.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= ccel_SaneronMember 		   
Condition for recording equity losses     0ccel_ConditionForRecordingEquityLossesOfAffiliateInvestmentBalance
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= ccel_SaneronMember 		     
Saneron [Member] | CCEL Bio-Therapies, Inc. [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Non-Controlling interest after merger         43.42%us-gaap_MinorityInterestOwnershipPercentageByParent
/ dei_LegalEntityAxis
= ccel_CcelBioTherapiesIncMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= ccel_SaneronMember 		 
Minimum [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Contracted storage periods     1 year      
Maximum [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Contracted storage periods     21 years      
Stock Option [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Number of outstanding options excluded from computation of diluted earnings per share     271,000us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_StockOptionMember 		496,001us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis
= us-gaap_StockOptionMember 		   
Saneron Therapeutics, Inc. [Member] | CCEL Bio-Therapies, Inc. [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary         260,000us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= ccel_SaneronTherapeuticsMember
/ dei_LegalEntityAxis
= ccel_CcelBioTherapiesIncMember 		 
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary         1,924,000us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
/ us-gaap_BusinessAcquisitionAxis
= ccel_SaneronTherapeuticsMember
/ dei_LegalEntityAxis
= ccel_CcelBioTherapiesIncMember 		 
Saneron Therapeutics, Inc. [Member] | Stem Cell Preservation Technologies, Inc. [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Issue of shares by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary         195,000us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= ccel_SaneronTherapeuticsMember
/ dei_LegalEntityAxis
= ccel_StemCellPreservationTechnologiesIncMember 		 
Fair value of shares issued by parent and another subsidiary of parent to the share holder of company merged with wholly owned subsidiary         $ 3,900us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
/ us-gaap_BusinessAcquisitionAxis
= ccel_SaneronTherapeuticsMember
/ dei_LegalEntityAxis
= ccel_StemCellPreservationTechnologiesIncMember 		 
Credit Concentration Risk [Member]            
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]            
Percentage of accounts receivable and advances due from certain foreign license affiliates       42.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CreditConcentrationRiskMember